AzTrials
AzTrials

Pain, PostoperativePhase 4NCT06410612

Block and Periarticular Injection Study

A Phase 4 study testing regional anesthesia and PAI and PAI in people with Pain, Postoperative, run by Washington University School of Medicine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to compare two types of perioperative analgesic modalities, adductor canal block plus interspace between popliteal artery and capsule of the knee (IPACK) block and periarticular injection versus periarticular injection alone, to determine their relative efficacies with regard to pain relief… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pain, Postoperative
What is being tested?
regional anesthesia and PAI and PAI
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
174 participants
Where
1 siteUnited States
Study dates
4 Mar 2024to 12 May 2025
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Planning to undergo Unilateral primary total knee arthroplasty.
  • 18 and up
  • Willing to sign informed consent
  • Willing to return for all follow-up visits
  • Smartphone or tablet device capable of running the FocusMotion platform

Who cannot join

  • BMI > 45
  • Preexisting functionally limiting neurologic disorders
  • Hepatic or renal insufficiency
  • History of unprovoked venous thromboembolism
  • Inability to complete baseline functional testing
  • Chronic opioid or gabapentin and pregabalin use (chronic defined as use >5 days per week prior to the surgical procedure)
Show all 10Show fewer
  • Allergy or intolerance to trial medications
  • Planned admission to a postoperative rehabilitation facility
  • Planned general anesthesia
  • Receiving workers compensation or disability payments

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Washington University School of Medicine

    Creve Coeur, Missouri, 63110

Other trials in United States

About this study

Official title: The Effect of Regional Anesthesia and Periarticular Injection and Versus Periarticular Injection Alone on Early Recovery After Total Knee Arthroplasty: A Prospective Randomized Trial

The purpose of the study is to compare two types of perioperative analgesic modalities, adductor canal block plus interspace between popliteal artery and capsule of the knee (IPACK) block and periarticular injection versus periarticular injection alone, to determine their relative efficacies with regard to pain relief and functional outcomes in the early postoperative period following primary total knee arthroplasty.

Read the detailed description

The widespread adoption of multimodal analgesia in contemporary total knee arthroplasty (TKA) has led to improvements in perioperative pain control, expedited recovery times, and shorter hospital stays1-3. Periarticular injections (PAIs), adductor canal blocks (ACBs), and interspace between popliteal artery and capsule of the knee (IPACK) blocks are commonly utilized as part of contemporary multimodal analgesia protocols, but their relative efficacies in improving early recovery after TKA has yet to be definitively elucidated4. There are a few known potential drawbacks of ACBs and IPACKs including surgical delay due to administration timing, increased costs, and small risks associated with a regional block. Both regional anesthesia and PAI have been found to be effective alone in improving pain and opioid consumption, but there is limited data on whether there is an additive benefit of providing both treatments for patients undergoing primary TKA. Therefore, the purpose of our study is to compare the efficacy of regional anesthesia and PAI vs. PAI alone for pain management and functional recovery in the early postoperative period following TKA.

Design Prospective randomized trial

Treatment Groups All ACBs will be administered as a single shot preoperatively in the holding area on the day of surgery by the regional anesthesia team and PAIs will be administered intraoperatively by the treating orthopaedic surgeon.

Group 1: regional anesthesia (ACB + IPACK) and PAI Group 2: PAI alone

Being tested
regional anesthesia and PAI, PAI
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • regional anesthesia and PAIDrug

    Also called adductor canal block, periarticular injection

    this is the block portion of the study

  • PAIDrug

    Also called Periarticular injections

    this is the no block portion of the study

Study groups in NCT06410612
Study groupRoleWhat they receive
Block and Periarticular injectionActive comparatorregional anesthesia (Adductor canal block +IPACK) and Periarticular injection
Receives: Drug: regional anesthesia and PAI; Drug: PAI
Periarticular injectin aloneActive comparatorPeriarticular injection alone
Receives: Drug: PAI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Visual Analog Scale (VAS) Pain Score for 2 Weeks Postoperatively

    pain score 0-10 10 being more pain

    Measured: at 2 weeks

Secondary outcomes (8)
  1. Opioid Use

    opioid medications survey Opioids calculated MMEs (morphine milligram equivalents) milligrams of opioids correlates with the morphine equivalents.

    Morphine equivalents are standard units used to compare the analgesic potency of different opioids to a reference dose of oral morphine. They calculate total daily, safe, and effective doses

    Measured: postop day 2

  2. Daily Step Count at 2 Weeks Postop

    step count throught fitbit

    Measured: 2 weeks postop

  3. Oxford Knee Score

    oxford knee survey through app, 0-48 scale 0 being min and 48 being max score assesses pain and function of the knee

    Score 0 to 19 May indicate severe knee arthritis requiring surgical intervention.

    Score 20 to 29 May indicate moderate to severe knee arthritis.

    Score 30 to 39 May indicate mild to moderate knee arthritis. Score 40 to 48 May indicate satisfactory joint function not requiring treatment.

    Measured: baseline

  4. Sleep Quality Via Survey That Patients Completed Ranging From Very Good Sleep and Fairly Good Sleep

    sleep quality through app surveys number of participants that answered survey in the app with choices of very good sleep to very bad sleep. 0=very good sleep, 1=fairly good sleep, 2=fairly bad sleep. 3=very bad sleep the outcome measures data table reflects the number or participants that scored 0-1 on the survey at the baseline timepoint.

    Measured: baseline % of very good sleep and fairly good sleep

  5. Oxford Knee Score

    oxford knee survey through app, 0-48 scale 0 being min and 48 being max assesses pain and function of the knee

    Score 0 to 19 May indicate severe knee arthritis requiring surgical intervention.

    Score 20 to 29 May indicate moderate to severe knee arthritis.

    Score 30 to 39 May indicate mild to moderate knee arthritis. Score 40 to 48 May indicate satisfactory joint function not requiring treatment.

    Measured: 7 days postop

  6. Oxford Knee Score

    oxford knee survey through app, 0-48 scale 0 being min and 48 being max assesses pain and function of the knee

    Score 0 to 19 May indicate severe knee arthritis requiring surgical intervention.

    Score 20 to 29 May indicate moderate to severe knee arthritis.

    Score 30 to 39 May indicate mild to moderate knee arthritis. Score 40 to 48 May indicate satisfactory joint function not requiring treatment.

    Measured: 14 days postop

  7. Sleep Quality Via App Surveys With Range of Very Good Sleep and Fairly Good Sleep

    sleep quality through app surveys number of participants that answered survey in the app with choices of very good sleep to very bad sleep. 0=very good sleep, 1=fairly good sleep, 2=fairly bad sleep. 3=very bad sleep the outcome measures data table reflects the number or participants that scored 0-1 on the survey at the 7 day timepoint.

    Measured: 7 days postop % of fairly good to very good sleep

  8. Sleep Quality Via App Surveys With Range of Very Good Sleep to Fairly Good Sleep

    sleep quality through app surveys number of participants that answered survey in the app with choices of very good sleep to very bad sleep. 0=very good sleep, 1=fairly good sleep, 2=fairly bad sleep. 3=very bad sleep the outcome measures data table reflects the number or participants that scored 0-1 on the survey at the 14 day timepoint.

    Measured: 14 days postop % of very good sleep to fairly good sleep

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2024
  2. Study start4 Mar 2024
  3. Primary completion12 May 2025
  4. Study completion12 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
patients will be randomized into 2 groups.
Masking
Single blind
Who is masked
Participant
Enrolment
174 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06410612
Sponsor's protocol ID
202311211
Status last verified
Apr 2026
First submitted
11 Mar 2024
Last updated
20 Apr 2026
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing regional anesthesia and PAI and PAI in people with Pain, Postoperative, run by Washington University School of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Visual Analog Scale (VAS) Pain Score for 2 Weeks Postoperatively (time frame: at 2 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in